# A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

> **NCT06971523** · PHASE1,PHASE2 · RECRUITING · sponsor: **CytosinLab Therapeutics Co., Ltd.** · enrollment: 224 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** CTS3497

## Key facts

- **NCT ID:** NCT06971523
- **Lead sponsor:** CytosinLab Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-25
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971523, "A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06971523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*